The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics

被引:94
作者
Fernandes, AI [1 ]
Gregoriadis, G [1 ]
机构
[1] Univ London, Sch Pharm, Ctr Drug Delivery Res, London WC1N 1AX, England
关键词
asparaginase; polysialic acids; protein delivery; antibody response;
D O I
10.1016/S0378-5173(01)00603-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Erwinia carotovora L-asparaginase was conjugated via the E-amino groups of its lysine residues with colominic acid (CA) (polysialic acid) of average molecular mass of 10 kDa by reductive amination in the presence of NaCNBH3. Polysialylation using 50-, 100- and 250-fold molar excess CA relative to the enzyme led to an increasing proportion of the enzyme's E-amino groups (5.8, 7.6 and 11.3%, respectively) being conjugated to CA. Polysialylated and native (intact) asparaginase were used to immunize mice intravenously. Results (total IgG immune responses) indicate that all preparations elicited antibody production against the enzyme moiety but not against the CA of the conjugates. Moreover, antibody titres appeared highest for the native enzyme and were generally reduced as the degree of polysialylation increased. In other experiments mice pre-immunized with native or polysialylated asparaginase, with anti-asparaginase antibodies;in their blood, were injected intravenously with the corresponding enzyme preparations. Results revealed that polysialylation reduces the antigenicity of asparaginase thus leading to circulatory half-lives (t1/2 beta) that were 3-4-fold greater than that of the native enzyme, and similar to those observed in naive, non-immunized mice. Our data suggest that polysialylation of therapeutic enzymes and other proteins may be useful in maintaining their pharmacokinetics in individuals with antibodies to the therapeutic proteins as a result of chronic treatment. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:215 / 224
页数:10
相关论文
共 35 条
[1]  
ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
Catty D., 1989, ANTIBODIES PRACTICAL, VII, P97
[4]   ANTIBODIES TO POLY[(2-]8)-ALPHA-N-ACETYLNEURAMINIC ACID] AND POLY[(2-]9)-ALPHA-N-ACETYLNEURAMINIC ACID] ARE ELICITED BY IMMUNIZATION OF MICE WITH ESCHERICHIA-COLI K92 CONJUGATES - POTENTIAL VACCINES FOR GROUP-B AND GROUP-C MENINGOCOCCI AND ESCHERICHIA-COLI K1 [J].
DEVI, SJN ;
ROBBINS, JB ;
SCHNEERSON, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) :7175-7179
[5]   Polysialylated asparaginase: preparation, activity and pharmacokinetics [J].
Fernandes, AI ;
Gregoriadis, G .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1341 (01) :26-34
[6]   Synthesis, characterization and properties of sialylated catalase [J].
Fernandes, AI ;
Gregoriadis, G .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1996, 1293 (01) :90-96
[7]   Polyethylene glycol modification: Relevance of improved methodology to tumour targeting [J].
Francis, GE ;
Delgado, C ;
Fisher, D ;
Malik, F ;
Agrawal, AK .
JOURNAL OF DRUG TARGETING, 1996, 3 (05) :321-&
[8]   THE CLINICAL EFFICACY OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS [J].
FUERTGES, F ;
ABUCHOWSKI, A .
JOURNAL OF CONTROLLED RELEASE, 1990, 11 (1-3) :139-148
[9]  
GOLDBERG AI, 1973, CANCER RES, V33, P256
[10]  
GRAY GR, 1978, CELL SURFACE CARBOHY, P583